Coherus Oncology (CHRS) Change in Receivables (2015 - 2026)
Coherus Oncology (CHRS) posted Change in Receivables of $4.3 million for Q1 2026, down 48.64% sequentially from $8.3 million in Q4 2025, and up 108.41% YoY from $2.1 million in Q1 2025.
Coherus Oncology (CHRS) Change in Receivables (2015 - 2026) Analysis & Trends
Coherus Oncology has reported Change in Receivables for 11 years, with the latest figure at $4.3 million in Q1 2026.
- Quarterly Change in Receivables rose 108.41% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$38.4 million (up 79.97% YoY) and the FY2025 annual result came in at -$93.6 million, up 37.36% from the prior year.
- Change in Receivables fell to $4.3 million in Q1 2026 per CHRS's latest filing, from $8.3 million in the prior quarter.
- Over five years, Change in Receivables peaked at $75.3 million in Q3 2023 and troughed at -$76.6 million in Q2 2024.
- A 5-year average of -$5.9 million and a median of -$6.0 million in 2022 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2023 and 2025: Change in Receivables surged 3084.96% in 2023, then sank 493.2% in 2025.
- Over 5 years, Change in Receivables stood at $18.8 million in 2022, then soared by 134.38% to $44.1 million in 2023, then sank by 227.85% to -$56.3 million in 2024, then jumped by 114.8% to $8.3 million in 2025, then slumped by 48.64% to $4.3 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $4.3 million, $8.3 million, and $4.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | -8.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.22 Mn |
| Jun 30, 2026 | -8.22 Mn |
| Mar 31, 2026 | 4.28 Mn |
| Mar 31, 2026 | 4.28 Mn |
| Dec 31, 2025 | 8.34 Mn |
| Dec 31, 2025 | 8.34 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Jun 30, 2025 | -55.27 Mn |
| Jun 30, 2025 | -55.27 Mn |
| Mar 31, 2025 | -50.89 Mn |
| Mar 31, 2025 | -50.89 Mn |
| Dec 31, 2024 | -56.33 Mn |
| Dec 31, 2024 | -56.33 Mn |
| Sep 30, 2024 | -7.81 Mn |
| Sep 30, 2024 | -7.81 Mn |
| Jun 30, 2024 | -76.64 Mn |
| Jun 30, 2024 | -76.64 Mn |
| Mar 31, 2024 | -8.58 Mn |
| Mar 31, 2024 | -8.58 Mn |